featured
ESMO 2016: Recap of Metastatic Breast Cancer
- Interview with
-
Lee
S.
Schwartzberg
MD, FACP
-
Lillie
D.
Shockney
RN, BS, MAS, HON-ONN-CG
-
Reshma
L.
Mahtani
DO
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748.
- Finn RS, Martin M, Rugo HS, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 507.
- Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-1936.
- Royce M, Villanueva C, Ozgurogluc M, et al. BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC). Paper presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 2220.
- Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 525.
- Rugo HS, Barve A, Waller CF, et al. Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab. Paper presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract LBA 16.
- Reinbolt RE, Tolliver K, Abdel-Rasoul M, et al. Decision impact analysis of comprehensive genomic profiling (CGP) in advanced breast cancer: A prospective study. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 11578.
Disclosure statements are available on the authors' profiles: